Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for obesity in older adults.
The agreement, signed on June 2, 2026, brings together Veru’s investigational therapy enobosarm and Novo Nordisk’s blockbuster weight-loss drug Wegovy.
Phase 2b Study to Assess Combination Approach
The PLATEAU clinical trial will evaluate the use of enobosarm alongside Wegovy (semaglutide injection) in older patients with obesity who are undergoing weight-loss treatment with Wegovy.
Enobosarm is an oral selective androgen receptor modulator (SARM) that Veru is developing as part of its broader metabolic health and obesity strategy.
The study is designed to examine the potential benefits of combining the two therapies in this patient population.
Novo Nordisk to Supply Wegovy
Under the terms of the agreement, Veru will serve as both sponsor and operator of the Phase 2b trial.
Novo Nordisk will provide Wegovy for the study at no cost, supporting the clinical programme while allowing Veru to retain responsibility for trial execution and development activities.
The arrangement gives Veru access to one of the leading GLP-1 obesity treatments while advancing its own clinical research efforts.
Collaboration Includes Clinical Insights
As part of the partnership, Veru will share knowledge and data related to obesity and weight-management studies with Novo Nordisk.
This includes information regarding trial design, methodology and clinical execution, as well as regular updates covering study progress, protocol modifications and safety findings.
The collaboration is intended to facilitate efficient study management while expanding understanding of combination approaches in obesity treatment.
Veru Retains Global Rights to Enobosarm
The company emphasized that it continues to hold full worldwide development and commercialization rights for enobosarm.
However, the agreement grants Novo Nordisk a right of first negotiation should Veru seek to develop, commercialize or license intellectual property involving enobosarm in combination with any Novo Nordisk GLP-1 product for any therapeutic indication.
The arrangement preserves Veru’s strategic flexibility while establishing a framework for potential future collaboration between the two companies in the growing obesity treatment market.